Introduction
Background
Piebaldism is a rare autosomal dominant disorder of melanocyte development characterized by a congenital white forelock and multiple symmetrical hypopigmented or depigmented macules. This striking phenotype of depigmented patches of skin and hair has been observed throughout history, with the first descriptions dating to early Egyptian, Greek, and Roman writings. Generation after generation demonstrated a distinctive predictable familial mark—a white forelock. Families have sometimes been known for this mark of distinction, carrying such surnames as Whitlock, Horlick, and Blaylock.
The word piebald itself has been attributed to a combination of the "pie" in the magpie (a bird of black and white plumage) and the "bald" of the bald eagle (the United States' national bird, which has a white feathered head).
Piebaldism is due to an absence of melanocytes in affected skin and hair follicles as a result of mutations of the KIT proto-oncogene.1 As of a 2001 review by Richards et al, 14 point mutations, 9 deletions, 2 nucleotide splice mutations, and 3 insertions of the KIT gene were believed to be mutations causing piebaldism.2 The severity of phenotypic expression in piebaldism correlates with the site of the mutation within the KIT gene. The most severe mutations seem to be dominant negative missense mutations of the intracellular tyrosine kinase domain, whereas mild piebaldism appears related to mutations occurring in the amino terminal extracellular ligand-binding domain with resultant haplo insufficiency.
Most piebald patients have the above-described mutation of the KIT gene encoding a tyrosine kinase receptor involved in pigment cell development.3 The white hair and patches of such patients are completely formed at birth and do not usually expand thereafter. However, 2 novel cases of piebaldism were described in which both mother and daughter had a novel Val620Ala mutation in their KIT gene and showed progressive depigmentation. These findings are consistent with the hypothesis that progressive piebaldism might result from digenic inheritance of the KIT (V620A) mutation that causes piebaldism and a second, unknown locus that causes progressive depigmentation.4
Piebaldism is one of the cutaneous signs of Waardenburg syndrome, along with heterochromia of the irides, lateral displacement of inner canthi, and deafness.5
Pathophysiology
Piebaldism is an autosomal dominant genetic disorder of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes. Piebaldism results from mutations of the KIT proto-oncogene, which encodes the cell surface receptor transmembrane tyrosine kinase for an embryonic growth factor, steel factor. Several pathologic mutations of the KIT gene now have been identified in different patients with piebaldism. Correlation of these mutations with the associated piebald phenotypes has led to the recognition of a hierarchy of 3 classes of mutations that result in a graded series of piebald phenotypes. KIT mutations in the vicinity of codon 620 lead to the usual phenotype of static piebaldism. Mutations of the KIT proto-oncogene produce variations in phenotype in relation to the site of the KIT gene mutation.
In a recent analysis of 26 unrelated patients with piebaldismlike hypopigmentation (ie, 17 typical patients, 5 patients with atypical clinical features or family histories, and 4 patients with other disorders that involve white spotting), novel pathologic mutations or deletions of the KIT gene were observed in 10 (59%) of the typical patients and in 2 (40%) of the atypical patients. Overall, pathologic KIT gene mutations were identified in 21 (75%) of 28 unrelated patients with typical piebaldism. Patients without apparent KIT mutations had no apparent abnormalities of the gene encoding steel factor itself; however, genetic linkage analyses in 2 of these families implied linkage of the piebald phenotype to KIT. Thus, most patients with typical piebaldism seem to have abnormalities of the KIT gene. A complex network of interacting genes regulates embryonic melanocyte development.
Piebaldism almost always has a static course. Genetic analysis of a mother and daughter with progressive piebaldism revealed a novel Val620Ala (1859T>C) mutation in the KIT gene. This KIT mutation affects the intracellular tyrosine kinase domain and implies a severe phenotype. This is a newly described phenotype with melanocyte instability leading to advancing loss of pigmentation and the progressive appearance of the hyperpigmented macules.
A South African girl of Xhosa ancestry with severe piebaldism and profound congenital sensorineural deafness had a novel missense substitution at a highly conserved residue in the intracellular kinase domain of the KIT proto-oncogene, R796G. Although auditory anomalies in mice with dominant white spotting due to KIT mutations may occur, deafness is not typical in human piebaldism. Thus, sensorineural deafness extends considerably the phenotypic range of piebaldism due to KIT gene mutation in humans and strengthens the clinical similarity between piebaldism and the various forms of Waardenburg syndrome.
Manipulation of the mouse genome may be an important approach for studying gene function and establishing human disease models.6 Mouse mutants generated and screened for dominant mutations yielded several mice with fur color abnormalities. One causes a phenotype similar to dominant-white spotting (W) allele mutants. This strain may serve as a new disease model of human piebaldism.
Mortality/Morbidity
Piebaldism is a benign disorder.
Clinical
History
- Graft versus host disease may arise solely within an area affected by piebaldism; therefore, piebaldism-affected skin may be immunologically different from normal skin.7
Physical
- The white forelock is evident in 80-90% of those affected.
- Both hair and skin in the central frontal scalp are permanently white from birth or when hair color first becomes apparent. Regression of the white forelock has been described.8
- The forelock and white skin may have a triangular shape.
- The eyebrow and eyelash hair may also be affected, either continuously or discontinuously with the forelock.
- White spots may be observed on the face, trunk, and extremities and tend to be symmetrical in distribution and irregular in shape.
- They represent a focal lack of melanocytes.
- This depigmented skin may show a narrow border of hyperpigmentation or island of pigmentation and has white hair that is otherwise normal emanating from it.
- White patches of hair may be located other than frontally in some patients.
- The only pigmentation change of skin or hair may be a white forelock in some patients.
Causes
- Piebaldism is a rare autosomal dominant genetic disorder.
More on Piebaldism |
 Overview: Piebaldism |
| Differential Diagnoses & Workup: Piebaldism |
| Treatment & Medication: Piebaldism |
| Follow-up: Piebaldism |
| Multimedia: Piebaldism |
| References |
| Next Page » |
References
Ezoe K, Holmes SA, Ho L, et al. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am J Hum Genet. Jan 1995;56(1):58-66. [Medline].
Richards KA, Fukai K, Oiso N, Paller AS. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. Feb 2001;44(2):288-92. [Medline].
Tosaki H, Kunisada T, Motohashi T, Aoki H, Yoshida H, Kitajima Y. Mice transgenic for Kit(V620A): recapitulation of piebaldism but not progressive depigmentation seen in humans with this mutation. J Invest Dermatol. May 2006;126(5):1111-8. [Medline].
Spritz RA. "Out, damned spot!". J Invest Dermatol. May 2006;126(5):949-51. [Medline].
Jan IA, Stroedter L, Haq AU, Din ZU. Association of Shah-Waardenburgh syndrome: a review of 6 cases. J Pediatr Surg. Apr 2008;43(4):744-7. [Medline].
Ruan HB, Zhang N, Gao X. Identification of a novel point mutation of mouse proto-oncogene c-kit through N-ethyl-N-nitrosourea mutagenesis. Genetics. Feb 2005;169(2):819-31. [Medline].
Chow RK, Stewart WD, Ho VC. Graft-versus-host reaction affecting lesional skin but not normal skin in a patient with piebaldism. Br J Dermatol. Jan 1996;134(1):134-7. [Medline].
Matsunaga H, Tanioka M, Utani A, Miyachi Y. Familial case of piebaldism with regression of white forelock. Clin Exp Dermatol. Jul 2008;33(4):511-2. [Medline].
Tamayo ML, Gelvez N, Rodriguez M, Florez S, Varon C, Medina D, et al. Screening program for Waardenburg syndrome in Colombia: clinical definition and phenotypic variability. Am J Med Genet A. Apr 15 2008;146A(8):1026-31. [Medline].
Njoo MD, Nieuweboer-Krobotova L, Westerhof W. Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol. Nov 1998;139(5):829-33. [Medline].
Garg T, Khaitan BK, Manchanda Y. Autologous punch grafting for repigmentation in piebaldism. J Dermatol. Nov 2003;30(11):849-50. [Medline].
Desch LW. White forelock could be early sign of tuberous sclerosis. Arch Pediatr Adolesc Med. Jun 1996;150(6):651-2. [Medline].
Falabella R, Barona M, Escobar C, Borrero I, Arrunategui A. Surgical combination therapy for vitiligo and piebaldism. Dermatol Surg. Oct 1995;21(10):852-7. [Medline].
Farag TI, el-Ramly MA, Sakr MF. A Bedouin kindred with 19 piebalds in 5 generations. Clin Genet. Dec 1992;42(6):326-8. [Medline].
Janjua SA, Khachemoune A, Guldbakke KK. Piebaldism: a case report and a concise review of the literature. Cutis. Nov 2007;80(5):411-4. [Medline].
Murakami T, Fukai K, Oiso N. New KIT mutations in patients with piebaldism. J Dermatol Sci. Jun 2004;35(1):29-33. [Medline].
Murakami T, Hosomi N, Oiso N, et al. Analysis of KIT, SCF, and initial screening of SLUG in patients with piebaldism. J Invest Dermatol. Mar 2005;124(3):670-2. [Medline].
Nomura K, Hatayama I, Narita T, Kaneko T, Shiraishi M. A novel KIT gene missense mutation in a Japanese family with piebaldism. J Invest Dermatol. Aug 1998;111(2):337-8. [Medline].
Spritz RA. Molecular basis of human piebaldism. J Invest Dermatol. Nov 1994;103(5 Suppl):137S-140S. [Medline].
Spritz RA. Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Semin Cutan Med Surg. Mar 1997;16(1):15-23. [Medline].
Spritz RA, Beighton P. Piebaldism with deafness: molecular evidence for an expanded syndrome. Am J Med Genet. Jan 6 1998;75(1):101-3. [Medline].
Syrris P, Malik NM, Murday VA, Patton MA, et al. Three novel mutations of the proto-oncogene KIT cause human piebaldism. Am J Med Genet. Nov 6 2000;95(1):79-81. [Medline].
Thomas I, Kihiczak GG, Fox MD, Janniger CK, Schwartz RA. Piebaldism: an update. Int J Dermatol. Oct 2004;43(10):716-9. [Medline].
Ward KA, Moss C, Sanders DS. Human piebaldism: relationship between phenotype and site of kit gene mutation. Br J Dermatol. Jun 1995;132(6):929-35. [Medline].
Further Reading
Keywords
piebaldism, partial albinism, familial white spotting, white forelock, poliosis circumscriptum, Waardenburg syndrome, KIT proto-oncogene
